### Edgar Filing: HBM BIOVENTURES CAYMAN LTD - Form 3

#### HBM BIOVENTURES CAYMAN LTD

Form 3

February 02, 2011

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

Expires:

response...

3235-0104

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

January 31, 2005

Estimated average burden hours per

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement Pacira Pharmaceuticals, Inc. [PCRX]  **HBM BIOVENTURES** (Month/Day/Year) **CAYMAN LTD** 02/02/2011 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) CENTENNIAL TOWERS, 3RD (Check all applicable) FLOOR., 2454 WEST BAY ROAD \_\_X\_\_ 10% Owner Director (Street) Officer Other 6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) \_X\_ Form filed by One Reporting Person GRAND CAYMAN, CAYMAN Form filed by More than One **ISLANDSÂ** Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Â Common Stock 92,980 D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

required to respond unless the form displays a

currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: HBM BIOVENTURES CAYMAN LTD - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Series A Convertible Stock	(1)	(1)	Common Stock	1,487,680	\$ <u>(1)</u>	D	Â
Common Stock Warrant s(Right to Buy)	01/22/2009	01/21/2014	Common Stock	37,192	\$ 2.69	D	Â
Common Stock Warrants (Right to Buy)	12/29/2010	12/29/2017	Common Stock	41,841	\$ 13.44	D	Â
Convertible Promissory Notes	(2)	(2)	Common Stock	1,021,223	\$ <u>(2)</u>	D	Â

### **Reporting Owners**

		Relationships			
% Owner	Officer	Other			
ÂX	Â	Â			
		% Owner Officer $\hat{A} X \qquad \hat{A}$			

# **Signatures**

/s/ John Arnold, Chairman and Managing
Director
02/02/2011

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

- (1) The Series A convertible preferred s tock has no expiration date and will automatically convert into Common Stock upon the consummation of the Issuer's initial public offering.
- (2) All principal and accrued interest due on these convertible promissory notes will automatically convert into shares of Common Stock upon the consummation of the Issuer's initial public offering at an effective conversion price of approximately \$13.44 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2